pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

Drug Discovery World

FEBRUARY 5, 2024

Through early diagnosis and precision medicine, we can improve quality of life and enable more people with cancer to survive. Dr Gen Li, Founder and President, Phesi “In 2024, we can expect immunotherapy trials to become a driving force for change in clinical development.

Research 116

Research Gene Sequencing Drug Delivery Systems Trials 116

Pharmaceutical Technology

MAY 26, 2023

As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA. Biopharmaceutical companies like Pfizer and Lonza have announced licensing agreements to use the doggybone in their own respective research.

DNA 130

DNA Manufacturing Gene Therapy Gene 130